The content on this site is intended for healthcare professionals only
Dr Michel Delforge speaks to ecancer about the impact of Idecabtagene Vicleucel (Ide-Cel) as compared to standard regimens on the HRQoL of patients with Triple-Class-Exposed (TCE) relapsed/refractory multiple myeloma (RRMM) who have received at least 3–4 prior regimens including an immunomodulatory agent, a proteasome inhibitor, and daratumumab (an anti-CD38 monoclonal antibody) using data from the KarMMa-3 study.
The findings, as reported by the patients, reveal that Ide-Cel treatment significantly improves MM-relevant disease symptoms, functioning, and overall health status. The results further support the superiority of Ide-Cel over standard regimens for this patient population.
Overall, Ide-Cel treatment can help alleviate the negative impact on HRQoL in patients with multiple myeloma.
Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL
